Takeda has taken part in a series B round for therapeutic antibody developer Maverick Therapeutics as part of a collaboration deal sized at up to $125m in total.
US-based therapeutic antibody developer Maverick Therapeutics has raised $23m in series B funding from investors including pharmaceutical company Takeda as part of a $125m financing package.
Venture capital firm MPM Capital also took part in the equity portion, through its BioVentures 2014 and UBS Oncology Impact funds. The overall financing includes payments from Takeda related to upfront options and research and development.
Spun out of antibody development startup Harpoon Therapeutics in 2016 and initially financed by MPM Capital, Maverick is…
